Sodium-glucose cotransporter 2 inhibitors (SGLT2i): Their role in cardiometabolic risk management

Current Pharmaceutical Design

Volumn 23, Issue 10, 2017, Pages 1522-1532

  Katsiki, Niki ^a   Mikhailidis, Dimitri P ^b   Theodorakis, Michael J ^c  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Canagliflozin; Cardiovascular outcome trials; Cardiovascular risk factors; Dapagliflozin; Empagliflozin; Microvascular complications; Renoprotection; Sodium glucose cotransporter 2 inhibitors

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EMPAGLIFLOZIN; ERTUGLIFLOZIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IPRAGLIFLOZIN; LIPID; LIRAGLUTIDE; LUSEOGLIFLOZIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; REMOGLIFLOZIN; SERGLIFLOZIN ETABONATE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SOTAGLIFLOZIN; TOFOGLIFLOZIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2;

ARTERIAL STIFFNESS; BLOOD PRESSURE; BODY WEIGHT; CARDIOMETABOLIC RISK; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; DEHYDRATION; DISEASE COURSE; DIURESIS; DRUG MECHANISM; FLUID RETENTION; FRACTURE; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; KIDNEY FUNCTION; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORTHOSTATIC HYPOTENSION; OXIDATIVE STRESS; PATIENT CARE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; SODIUM RETENTION; URIC ACID BLOOD LEVEL; UROGENITAL TRACT INFECTION; VASCULAR RESISTANCE; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASE; RISK FACTOR;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; RISK FACTORS; RISK MANAGEMENT; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85015145621     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612823666170113152742     Document Type: Review

References (204)

1. Wilding JP. The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism 2014; 63(10): 1228-37.
2. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 2012; 14(1): 5-14.
3. Mudaliar S, Polidori D, Zambrowicz B, Henry RR. Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside. Diabetes Care 2015; 38(12): 2344-53.
4. Mitrakou A. Kidney: its impact on glucose homeostasis and hormonal regulation. Diabetes Res Clin Pract 2011; 93 Suppl 1: S66-72.
5. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58(4): 773-95.
6. Washburn WN, Poucher SM. Differentiating sodium-glucose cotransporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 2013; 22(4): 463-86.
7. Kalra S, Singh V, Nagrale D. Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review. Adv Ther 2016 Jul 16. [Epub ahead of print]
8. Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract 2014; 104(3): 297-22.
9. Opie LH. Sodium glucose co-transporter 2 (SGLT2) inhibitors: new among antidiabetic drugs. Cardiovasc Drugs Ther 2014; 28(4): 331-4.
10. http://care.diabetesjournals.org/content/suppl/2015/12/21/39.Supplement_1.DC2/2016-Standards-of-Care.pdf Last accessed 22 Sep 2016
11. https://www.nice.org.uk/guidance/ng28/chapter/1-recommendations Last accessed 22 Sep 2016
12. Schwartz SS, Ahmed I. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes. Curr Med Res Opin 2016; 32(5): 907-19.
13. Watts NB, Bilezikian JP, Usiskin K, et al. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab 2016; 101(1): 157-66.
14. Tang HL, Li DD, Zhang JJ, et al. Lack of Evidence for a Harmful Effect of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors on Fracture Risk among Type 2 Diabetes Patients: A Network and Cumulative Meta-Analysis of Randomized Controlled Trials. Diabetes Obes Metab 2016 Jul 13. [Epub ahead of print]
15. http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm Last accessed 22 Sep 2016
16. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm506554.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery Last accessed 22 Sep 2016
17. Scheen AJ. Pharmacodynamics, efficacy and safety of sodiumglucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015; 75(1): 33-59.
18. Singh AK. Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight. Indian J Endocrinol Metab 2015; 19(6): 722-30.
19. Yanai H, Katsuyama H, Hamasaki H, et al. Sodium-glucose cotransporter 2 inhibitors: possible anti-atherosclerotic effects beyond glucose lowering. J Clin Med Res 2016; 8(1): 10-4.
20. Lapuerta P, Zambrowicz B, Strumph P, Sands A. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor. Diab Vasc Dis Res 2015; 12(2): 101-10.
21. Lehmann A, Hornby PJ. Intestinal SGLT1 in metabolic health and disease. Am J Physiol Gastrointest Liver Physiol 2016; 310(11): G887-98.
22. Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action. J Diabetes Investig 2014; 5(3): 265-75.
23. Farch K, Vistisen D, Johansen NB, Jorgensen ME. Cardiovascular risk stratification and management in pre-diabetes. Curr Diab Rep 2014; 14(6): 493.
24. Gerich J. Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. Int J Gen Med 2013; 6: 877-95.
25. Fysekidis M, Cosson E, Banu I, Duteil R, Cyrille C, Valensi P. Increased glycemic variability and decrease of the postprandial glucose contribution to HbA1c in obese subjects across the glycemic continuum from normal glycemia to first time diagnosed diabetes. Metabolism 2014; 63(12): 1553-61.
26. Whaley JM, Tirmenstein M, Reilly TP, et al. Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2012; 5: 135-48.
27. Toderika Y, Ferguson N. Canagliflozin: a new class of antidiabetic agent targeting the sodium-glucose cotransporter. Cardiol Rev 2014; 22(2): 97-104.
28. Munir KM, Davis SN. Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes. Clin Pharmacol 2016; 8: 19-34.
29. Nishimura R, Tanaka Y, Koiwai K, et al. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study. Cardiovasc Diabetol 2015; 14: 11.
30. Kaku K, Watada H, Iwamoto Y, et al; Tofogliflozin 003 Study Group. Efficacy and safety of monotherapy with the novel sodium/ glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol 2014; 13: 65.
31. Kadokura T, Akiyama N, Kashiwagi A, et al. Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, double blind, placebocontrolled study. Diabetes Res Clin Pract 2014; 106(1): 50-6.
32. Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin 2014; 30(7): 1245-55.
33. Plosker GL. Dapagliflozin: A review of its use in type 2 diabetes mellitus. Drugs 2012; 72(17): 2289-312.
34. Vivian E. Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus. Diabetes Educ 2015; 41(1 Suppl): 5S-18S.
35. Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network metaanalysis. Diabetes Obes Metab 2016; 18(8): 783-94.
36. Rosenwasser RF, Rosenwasser JN, Sutton D, Choksi R, Epstein B. Tofogliflozin: a highly selective SGLT2 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc) 2014; 50(11): 739-45.
37. Hedrington MS, Davis SN. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol 2015; 11(4): 613-23.
38. Sakai S, Kaku K, Seino Y, et al. Efficacy and safety of the SGLT2 inhibitor luseogliflozin in japanese patients with type 2 diabetes mellitus stratified according to baseline body mass index: pooled analysis of data from 52-week phase III trials. Clin Ther 2016; 38(4): 843-862.e9.
39. Cariou B, Charbonnel B. Sotagliflozin as a potential treatment for type 2 diabetes mellitus. Expert Opin Investig Drugs 2015; 24(12): 1647-56.
40. Fujimori Y, Katsuno K, Ojima K, et al. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 2009; 609(1-3): 148-54.
41. Hussey EK, Clark RV, Amin DM, et al. Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. J Clin Pharmacol 2010; 50(6): 623-35.
42. Amin NB, Wang X, Jain SM, Lee DS, Nucci G, Rusnak JM. Doseranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes Obes Metab 2015; 17(6): 591-8.
43. Mikhail N. Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus. Expert Opin Investig Drugs 2015; 24(10): 1381-7.
44. Gorst C, Kwok CS, Aslam S, et al. Long-term glycemic variability and risk of adverse outcomes: a systematic review and metaanalysis. Diabetes Care 2015; 38(12): 2354-69.
45. Suh S, Kim JH. Glycemic variability: how do we measure it and why is it important? Diabetes Metab J 2015; 39(4): 273-82.
46. Samukawa Y, Omiya H, Watase H, Nozaki K, Sakai S, Nishimura R. Substantial effects of luseogliflozin revealed by analyzing responses to postprandial hyperglycemia: post hoc subanalyses of a randomized controlled study. Adv Ther 2016; 33(7): 1215-30.
47. Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care 2015; 38(3): 412-9.
48. Perkins BA, Cherney DZ, Soleymanlou N, et al. Diurnal glycemic patterns during an 8-week open-label proof-of-concept trial of empagliflozin in type 1 diabetes. PLoS One 2015; 10(11): e0141085.
49. Sun YN, Zhou Y, Chen X, Che WS, Leung SW. The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials. BMJ Open 2014; 4(4): e004619.
50. Yang XP, Lai D, Zhong XY, Shen HP, Huang YL. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. Eur J Clin Pharmacol 2014; 70(10): 1149-58.
51. Liakos A, Karagiannis T, Athanasiadou E, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and metaanalysis. Diabetes Obes Metab 2014; 16(10): 984-93.
52. Ikeda S, Takano Y, Cynshi O, et al. A novel and selective sodiumglucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2015; 17(10): 984-93.
53. Ohkura T. Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan. World J Diabetes 2015; 6(1): 136-44.
54. Seino Y. Luseogliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother 2014; 15(18): 2741-9.
55. Sykes AP, O’Connor-Semmes R, Dobbins R, et al. Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes. Diabetes Obes Metab 2015; 17(1): 94-7.
56. Rosenstock J, Cefalu WT, Lapuerta P, et al. Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy. Diabetes Care 2015; 38(3): 431-8.
57. Hussey EK, Dobbins RL, Stoltz RR, et al. Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study. J Clin Pharmacol 2010; 50(6): 636-46.
58. Saeed MA, Narendran P. Dapagliflozin for the treatment of type 2 diabetes: a review of the literature. Drug Des Devel Ther 2014; 8: 2493-505.
59. Blonde L, Stenlof K, Fung A, Xie J, Canovatchel W, Meininger G. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgrad Med 2016; 128(4): 371-80.
60. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014; 16(5): 457-66.
61. Katsiki N, Papanas N, Mikhailidis DP. Dapagliflozin: more than just another oral glucose-lowering agent? Expert Opin Investig Drugs 2010; 19(12): 1581-9.
62. Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97(3): 1020-31.
63. Katsiki N, Athyros VG, Mikhailidis DP. Abnormal peri-organ or intra-organ fat (APIFat) deposition: an underestimated predictor of vascular risk? Curr Vasc Pharmacol 2016 Jul 22. [Epub ahead of print] PubMed PMID: 27456108.
64. Katsiki N, Mikhailidis DP, Wierzbicki AS. Epicardial fat and vascular risk: a narrative review. Curr Opin Cardiol 2013; 28(4): 458-63.
65. Smith U. Abdominal obesity: a marker of ectopic fat accumulation. J Clin Invest 2015; 125(5): 1790-2.
66. Neeland IJ, McGuire DK, Chilton R, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res 2016; 13(2): 119-26.
67. Liakos A, Karagiannis T, Bekiari E, Boura P, Tsapas A. Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab 2015; 6(2): 61-7.
68. Yokono M, Takasu T, Hayashizaki Y, et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol 2014; 727: 66-74.
69. Yamamoto C, Miyoshi H, Ono K, et al. Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy. Endocr J 2016; 63(6): 589-96.
70. Iizuka T, Iemitsu K, Takihata M, et al. Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study. J Clin Med Res 2016; 8(2): 116-25.
71. Targher G, Marchesini G, Byrne CD. Risk of type 2 diabetes in patients with nonalcoholic fatty liver disease: Causal association or epiphenomenon? Diabetes Metab 2016; 42(3): 142-56.
72. Cusi K. Treatment of patients with type 2 diabetes and nonalcoholic fatty liver disease: current approaches and future directions. Diabetologia 2016; 59(6): 1112-20.
73. Katsiki N, Athyros VG, Karagiannis A, Wierzbicki AS, Mikhailidis DP. Should we expand the concept of coronary heart disease equivalents? Curr Opin Cardiol 2014; 29(4): 389-95.
74. Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism 2016; 65(8): 1109-23.
75. Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol 2015; 21(22): 6820-34.
76. Jojima T, Tomotsune T, Iijima T, Akimoto K, Suzuki K, Aso Y. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol Metab Syndr 2016; 8: 45.
77. Liang Y, Arakawa K, Ueta K, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 2012; 7(2): e30555.
78. Komiya C, Tsuchiya K, Shiba K, et al. Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction. PLoS One 2016; 11(3): e0151511.
79. Suzuki M, Takeda M, Kito A, et al. Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr Diabetes 2014; 4: e125.
80. Obata A, Kubota N, Kubota T, et al. Tofogliflozin improves insulin resistance in skeletal muscle and accelerates lipolysis in adipose tissue in male mice. Endocrinology 2016; 157(3): 1029-42.
81. Nakano S, Katsuno K, Isaji M, et al. Remogliflozin etabonate improves fatty liver disease in diet-induced obese male mice. J Clin Exp Hepatol 2015; 5(3): 190-8.
82. Qiang S, Nakatsu Y, Seno Y, et al. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr 2015; 7: 104.
83. Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials Diab Vasc Dis Res 2015; 12: 90-100.
84. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose cotransport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012; 44(4): 375-93.
85. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014; 8(4): 262-75.e9.
86. Imprialos KP, Sarafidis PA, Karagiannis AI. Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class? J Hypertens 2015; 33(11): 2185-97.
87. Maegawa H, Tobe K, Tabuchi H, Nakamura I. Baseline characteristics and interim (3-month) efficacy and safety data from STELLALONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice. Expert Opin Pharmacother 2016 Jul 27. [Epub ahead of print]
88. Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 2012; 92(2): 158-69.
89. Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol 2016; 4(3): 211-20.
90. Weber MA, Mansfield TA, Alessi F, Iqbal N, Parikh S, Ptaszynska A. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade. Blood Press 2016; 25(2): 93-103.
91. Townsend RR, Machin I, Ren J, et al. Reductions in mean 24-hour ambulatory blood pressure after 6-week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension. J Clin Hypertens (Greenwich) 2016; 18(1): 43-52.
92. Tikkanen I, Narko K, Zeller C, et al; EMPA-REG BP Investigators. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 2015; 38(3): 420-8.
93. Cherney D, Cooper M, Tikkanen I, et al. 4B.01: Contrasting influences of renal function on blood pressure and hba1c reductions with empagliflozin in patients with type 2 diabetes and hypertension. J Hypertens 2015; 33 (Suppl 1): e53.
94. Maliha G, Townsend RR. SGLT2 inhibitors: their potential reduction in blood pressure. J Am Soc Hypertens 2015; 9(1): 48-53.
95. Tikkanen I, Chilton R, Johansen OE. Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension. Curr Opin Nephrol Hypertens 2016; 25(2): 81-6.
96. Ayala DE, Moya A, Crespo JJ, et al; Hygia Project Investigators. Circadian pattern of ambulatory blood pressure in hypertensive patients with and without type 2 diabetes. Chronobiol Int 2013; 30(1-2): 99-115.
97. Mori H, Okada Y, Kawaguchi M, Tanaka Y. A case of type 2 diabetes with a change from a non-dipper to a dipper blood pressure pattern by dapagliflozin. J UOEH 2016; 38(2): 149-53.
98. Rahman A, Kittikulsuth W, Fujisawa Y, et al. Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome. J Hypertens 2016; 34(5): 893-906.
99. Chilton R, Tikkanen I, Crowe S, et al. 4B.03: Empagliflozin reduces systolic blood pressure in dipper and non-dipper patients with type 2 diabetes and hypertension. J Hypertens 2015; 33 Suppl 1: e53.
100. Levine MJ. Empagliflozin for type 2 diabetes mellitus: an overview of phase 3 clinical trials. Curr Diabetes Rev 2016 Jun 13. [Epub ahead of print]
101. Sjöström CD, Johansson P, Ptaszynska A, List J, Johnsson E. Dapagliflozin lowers blood pressure in hypertensive and nonhypertensive patients with type 2 diabetes. Diab Vasc Dis Res 2015; 12(5): 352-8.
102. Zinman B, Wanner C, Lachin JM, et al, EMPA REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-28.
103. Gordin D, Groop PH. Aspects of hyperglycemia contribution to arterial stiffness and cardiovascular complications in patients with type 1 diabetes. J Diabetes Sci Technol 2016 Mar 7. pii: 1932296816636894. [Epub ahead of print]
104. Vlachopoulos C, Xaplanteris P, Aboyans V, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis 2015; 241(2): 507-32.
105. Kozakova M, Palombo C. Diabetes mellitus, arterial wall, and cardiovascular risk assessment. Int J Environ Res Public Health 2016; 13(2): 201.
106. Katsiki N, Koumaras C, Athyros VG, Karagiannis A. Thinking beyond traditional cardiovascular risk factors: the role of arterial stiffness in targeting residual risk. Angiology 2012; 63(1): 9-11.
107. Ghosh RK, Bandyopadhyay D, Hajra A, Biswas M, Gupta A. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies. Int J Cardiol 2016; 212: 29-36.
108. Michel MC, Mayoux E, Vallon V. A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans. Naunyn Schmiedebergs Arch Pharmacol 2015; 388(8): 801-16.
109. Cherney DZ, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014; 13: 28.
110. Chilton R, Tikkanen I, Cannon CP, et al. 4B.02: The sodium glucose cotransporter 2 inhibitor empagliflozin reduces blood pressure and markers of arterial stiffness and vascular resistance in type 2 diabetes. J Hypertens 2015; 33 (Suppl 1): e53.
111. Wu CF, Liu PY, Wu TJ, Hung Y, Yang SP, Lin GM. Therapeutic modification of arterial stiffness: An update and comprehensive review. World J Cardiol 2015; 7(11): 742-53.
112. Ohira M, Yamaguchi T, Saiki A, et al. Pioglitazone improves the cardio-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin. Diabetes Metab Syndr Obes 2014; 7: 313-9.
113. Duvnjak L, Blaslov K. Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus. Diabetol Metab Syndr 2016; 8: 26.
114. Koren S, Shemesh-Bar L, Tirosh A, et al. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes Technol Ther 2012; 14(7): 561-7.
115. Zografou I, Sampanis C, Gkaliagkousi E, et al. Effect of vildagliptin on hsCRP and arterial stiffness in patients with type 2 diabetes mellitus. Hormones (Athens) 2015; 14(1): 118-25.
116. Kiyici S, Ersoy C, Kaderli A, et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Res Clin Pract 2009; 86(1): 44-50.
117. Koumaras C, Tzimou M, Stavrinou E, et al. Role of antihypertensive drugs in arterial ’de-stiffening’ and central pulsatile hemodynamics. Am J Cardiovasc Drugs 2012; 12(3): 143-56.
118. Koumaras C, Tziomalos K, Stavrinou E, et al. Effects of reninangiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness. J Am Soc Hypertens 2014; 8(2): 74-82.
119. Papademetriou V, Katsiki N, Doumas M, Faselis C. Halting arterial aging in patients with cardiovascular disease: hypolipidemic and antihypertensive therapy. Curr Pharm Des 2014; 20(40): 6339-49.
120. Miyashita Y, Endo K, Saiki A, et al. Effect of ezetimibe monotherapy on lipid metabolism and arterial stiffness assessed by cardioankle vascular index in type 2 diabetic patients. J Atheroscler Thromb 2010; 17(10): 1070-6.
121. Fitchett D, Zinman B, Wanner C, et al; EMPA-REG OUTCOMER trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOMER trial. Eur Heart J 2016; 37(19): 1526-34.
122. Halimi S, Vergès B. Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab 2014; 40(6 Suppl 1): S28-34.
123. Matthaei S, Bowering K, Rohwedder K, Sugg J, Parikh S, Johnsson E. Durability and tolerability of dapagliflozin over 52 weeks as addon to metformin and sulphonylurea in type 2 diabetes. Diabetes Obes Metab 2015; 17(11): 1075–1084.
124. Bode B, Stenlof K, Harris S, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab 2015; 17(3): 294-303.
125. Usiskin K, Kline I, Fung A, Mayer C, Meininger G. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results. Postgrad Med 2014; 126(3): 16-34.
126. Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. Diabetes Care 2016; 39(5): 717-25.
127. Riser Taylor S, Harris KB. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy 2013; 33(9): 984-99.
128. Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care 2015; 38(3): 365-372
129. Wang Y, Hu X, Liu X, Wang Z. An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients. Ther Clin Risk Manag 2016; 12: 1113-31.
130. Ferrannini E, Baldi S, Frascerra S, et al. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes 2016; 65(5): 1190-5.
131. Briand F, Mayoux E, Brousseau E, et al. Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism. Diabetes 2016; 65(7): 2032-8.
132. Inagaki N, Goda M, Yokota S, Maruyama N, Iijima H. Effects of baseline blood pressure and low-density lipoprotein cholesterol on safety and efficacy of canagliflozin in japanese patients with type 2 diabetes mellitus. Adv Ther 2015; 32(11): 1085-103.
133. Katsiki N, Athyros VG, Karagiannis A. Achieving lipid targets in primary care settings. Curr Med Res Opin 2014; 30(10): 1971-4.
134. Nikolic D, Katsiki N, Montalto G, Isenovic ER, Mikhailidis DP, Rizzo M. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients 2013; 5(3): 928-48.
135. Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol 2011; 9(5): 531-2.
136. Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011; 9(5): 533-71.
137. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. The role of statins in the treatment of type 2 diabetes mellitus: an update. Curr Pharm Des 2014; 20(22): 3665-74.
138. Katsiki N, Nikolic D, Montalto G, Banach M, Mikhailidis DP, Rizzo M. The role of fibrate treatment in dyslipidemia: an overview. Curr Pharm Des.2013; 19(17): 3124-31.
139. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Ezetimibe and low density lipoprotein subfractions: an ongoing debate. Curr Med Res Opin 2011; 27(3): 693-5.
140. Rizzo M, Christ ER, Rini GB, Spinas GA, Berneis K. The differential effects of thiazolidinediones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance? Expert Opin Pharmacother 2008; 9(13): 2295-303.
141. Ariel D, Kim SH, Abbasi F, Lamendola CA, Liu A, Reaven GM. Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutr Metab Cardiovasc Dis 2014; 24(12): 1317-22.
142. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview. Curr Vasc Pharmacol 2014; 12(4): 627-41.
143. Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011; 9(3): 258-70.
144. Kolovou GD, Mikhailidis DP, Nordestgaard BG, Bilianou H, Panotopoulos G. Definition of postprandial lipaemia. Curr Vasc Pharmacol 2011 May; 9(3): 292-301.
145. Chan DC, Pang J, Romic G, Watts GF. Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies. Curr Atheroscler Rep 2013; 15(3): 309.
146. Scheen AJ. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. Postgrad Med 2013; 125(3): 7-20.
147. Eleftheriadou I, Grigoropoulou P, Katsilambros N, Tentolouris N. The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism. Curr Diabetes Rev 2008; 4(4): 340-56.
148. Katsiki N, Christou GA, Kiortsis DN. Liraglutide and cardiometabolic effects: more than just another antiobesity drug? Curr Vasc Pharmacol 2016; 14(1): 76-9.
149. Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011; 9(5): 533-71.
150. Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol 2011; 9(5): 531-2.
151. Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011; 9(3): 258-70.
152. Katsiki N, Karagiannis A, Athyros VG, Mikhailidis DP. Hyperuricaemia: more than just a cause of gout? J Cardiovasc Med (Hagerstown) 2013; 14(6): 397-402.
153. Katsiki N, Doumas M, Athyros VG, Karagiannis A. Hyperuricemia as a risk factor for cardiovascular disease. Expert Rev Cardiovasc Ther 2015; 13(1): 19-20.
154. Katsiki N, Mikhailidis DP. Hyperuricaemia in cardiovascular diseases: a passive or an active player? Med Princ Pract 2015; 24(3): 269-70.
155. Borghi C, Verardi FM, Pareo I, Bentivenga C, Cicero AF. Hyperuricemia and cardiovascular disease risk. Expert Rev Cardiovasc Ther 2014; 12(10): 1219-25.
156. Davies MJ, Trujillo A, Vijapurkar U, Damaraju CV, Meininger G. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2015; 17(4): 426-9.
157. Ptaszynska A, Hardy E, Johnsson E, Parikh S, List J. Effects of dapagliflozin on cardiovascular risk factors. Postgrad Med 2013; 125(3): 181-9.
158. Kashiwagi A, Yoshida S, Nakamura I, et al. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials. J Diabetes Investig 2016; 7(4): 544-54.
159. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol 2011; 9(6): 698-705.
160. Katsiki N, Papanas N, Fonseca VA, Maltezos E, Mikhailidis DP. Uric acid and diabetes: Is there a link? Curr Pharm Des 2013; 19(27): 4930-7.
161. Terami N, Ogawa D, Tachibana H, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One 2014; 9(6): e100777.
162. Oelze M, Kröller-Schön S, Welschof P, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS One 2014; 9(11): e112394.
163. Cheng ST, Chen L, Li SY, Mayoux E, Leung PS. The effects of empagliflozin, an SGLT2 inhibitor, on pancreatic β-cell mass and glucose homeostasis in type 1 diabetes. PLoS One 2016; 11(1): e0147391.
164. Panchapakesan U, Pegg K, Gross S, et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy? PLoS One 2013; 8(2): e54442.
165. Ishibashi Y, Matsui T, Yamagishi S. Tofogliflozin, a highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation. Horm Metab Res 2016; 48(3): 191-5.
166. Tahara A, Kurosaki E, Yokono M, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol 2013; 715(1-3): 246-55.
167. Tahara A, Kurosaki E, Yokono M, et al. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin induced type 1 diabetic rats. J Pharm Pharmacol 2014; 66(7): 975-87.
168. Okamoto A, Yokokawa H, Sanada H, Naito T. Changes in levels of biomarkers associated with adipocyte function and insulin and glucagon kinetics during treatment with dapagliflozin among obese type 2 diabetes mellitus patients. Drugs R D 2016 Jun 22. [Epub ahead of print]
169. Wanner C, Inzucchi SE, Lachin JM, et al; EMPA-REG OUTCOME investigators. empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med.2016; 375(4): 323-34.
170. Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L. The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol 2016; 29(3): 391-400.
171. Mende C, Katz A. Cystatin C-and creatinine-based estimates of glomerular filtration rate in dapagliflozin phase 3 clinical trials. Diabetes Ther 2016; 7(1): 139-51.
172. Gilbert RE, Weir MR, Fioretto P, et al. Impact of age and estimated glomerular filtration rate on the glycemic efficacy and safety of canagliflozin: a pooled analysis of clinical studies. Can J Diabetes 2016; 40(3): 247-57.
173. Jinnouchi H, Nozaki K, Watase H, Omiya H, Sakai S, Samukawa Y. Impact of reduced renal function on the glucose-lowering effects of luseogliflozin, a selective sglt2 inhibitor, assessed by continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus. Adv Ther 2016; 33(3): 460-79.
174. Zambrowicz B, Lapuerta P, Strumph P, et al. LX4211 therapy reduces postprandial glucose levels in patients with type 2 diabetes mellitus and renal impairment despite low urinary glucose excretion. Clin Ther 2015; 37(1): 71-82.e12.
175. Weir MR. The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors. Postgrad Med 2016; 128(3): 290-8.
176. Heerspink HJ, Johnsson E, Gause-Nilsson I, Cain VA, Sjostrom CD. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab 2016; 18(6): 590-7.
177. Fioretto P, Stefansson BV, Johnsson E, Cain VA, Sjostrom CD. Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment. Diabetologia 2016; 59(9): 2036-9.
178. Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 2016 Aug 18. pii: ASN.2016030278. [Epub ahead of print]
179. Cherney D, Lund SS, Perkins BA, et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia 2016; 59(9): 1860-70.
180. Ojima A, Matsui T, Nishino Y, Nakamura N, Yamagishi S. Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts antiinflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis. Horm Metab Res 2015; 47(9): 686-92.
181. Škrtić M, Cherney DZ. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens 2015; 24(1): 96-103.
182. Sonesson C, Johansson PA, Johnsson E, Gause-Nilsson I. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol 2016; 15: 37.
183. Savarese G, Perrone-Filardi P, D’Amore C, et al. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis. Int J Cardiol 2015; 181: 239-44.
184. Wu JH, Foote C, Blomster J, Toyama T, Perkovic V, Sundstrom J, Neal B. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2016; 4(5): 411-9.
185. Boonman-de Winter LJ, Rutten FH, Cramer MJ, et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia 2012; 55(8): 2154-62.
186. Shi C, Wang LJ, Hu DF, et al. Prevalence, clinical characteristics and outcome in patients with chronic heart failure and diabetes. Chin Med J (Engl) 2010; 123(6): 646-50.
187. Zhong J, Goud A, Rajagopalan S. Glycemia Lowering and Risk for Heart Failure: Recent Evidence from Studies of Dipeptidyl Peptidase Inhibition. Circ Heart Fail 2015; 8(4): 819-25.
188. Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34, 000 patients. Circ Heart Fail 2013; 6: 395–402.
189. Standl E, Schnell O, McGuire DK. Heart failure considerations of antihyperglycemic medications for type 2 diabetes. Circ Res 2016; 118(11): 1830-43.
190. Scirica BM, Bhatt DL, Braunwald E, et al; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369(14): 1317-26.
191. White WB, Cannon CP, Heller SR, et al. EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327–1335.
192. Zannad F, Cannon CP, Cushman WC, et al. EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015; 385: 2067-2076.
193. 193] Green JB, Bethel MA, Armstrong PW, et al. TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232-242.
194. Li L, Li S, Deng K, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and metaanalysis of randomised and observational studies. BMJ 2016; 352: i610.
195. Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55, 141 participants. Cardiovasc Ther 2014; 32(4): 147-58.
196. Li L, Li S, Liu J, et al. Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and metaanalysis of randomized and observational studies. BMC Cardiovasc Disord 2016; 16: 91.
197. Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER steering committee; LEADER trial investigators. liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375(4): 311-22.
198. Tanaka A, Inoue T, Kitakaze M, et al. Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. Cardiovasc Diabetol 2016; 15: 57.
199. Takeuchi T, Dohi K, Omori T, et al. Diuretic effects of sodiumglucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure. Int J Cardiol 2015; 201: 1-3.
200. Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia 2016; 59(7): 1333-9.
201. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? a unifying hypothesis. Diabetes Care 2016; 39(7): 1115-22.
202. Hamouda NN, Sydorenko V, Qureshi MA, Alkaabi JM, Oz M, Howarth FC. Dapagliflozin reduces the amplitude of shortening and Ca(2+) transient in ventricular myocytes from streptozotocininduced diabetic rats. Mol Cell Biochem 2015; 400(1-2): 57-68.
203. Ring A, Brand T, Macha S, et al. The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study. Cardiovasc Diabetol 2013; 12: 70.
204. Carlson GF, Tou CK, Parikh S, Birmingham BK, Butler K. Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study. Diabetes Ther 2011; 2(3): 123-32